Bioventix PLC (LON:BVXP)‘s stock had its “corporate” rating reissued by equities researchers at FinnCap in a research report issued to clients and investors on Tuesday. They presently have a GBX 1,450 ($17.99) price target on the biotechnology company’s stock. FinnCap’s target price points to a potential upside of 9.19% from the stock’s current price.

Bioventix PLC (LON:BVXP) opened at 1328.00 on Tuesday. Bioventix PLC has a one year low of GBX 899.50 and a one year high of GBX 1,600.00. The firm has a 50-day moving average of GBX 1,385.40 and a 200-day moving average of GBX 1,121.62. The company’s market capitalization is GBX 67.06 million.

The firm also recently declared a dividend, which was paid on Friday, November 11th. Stockholders of record on Thursday, October 27th were issued a dividend of GBX 46 ($0.57) per share. The ex-dividend date of this dividend was Thursday, October 27th. This is a boost from Bioventix PLC’s previous dividend of $16.50. This represents a dividend yield of 3.15%.

ILLEGAL ACTIVITY NOTICE: This story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be read at

In other news, insider Ian James Nicholson sold 2,000 shares of the stock in a transaction on Friday, November 18th. The stock was sold at an average price of GBX 1,300 ($16.13), for a total transaction of £26,000 ($32,254.06).

Bioventix PLC Company Profile

Bioventix PLC, based in the United Kingdom, is engaged in the development and supply of antibodies. The Company is a biotechnology company specializing in the development of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing.

Receive News & Stock Ratings for Bioventix PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventix PLC and related stocks with our FREE daily email newsletter.